Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Datamonitors' URL Pharma, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by URL Pharma, Inc. since January 2007.
– Provides intelligence on URL Pharma, Inc.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by URL Pharma, Inc. and its subsidiaries since 2007. – Information about key financial and legal advisors for URL Pharma, Inc.'s financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
This report includes URL Pharma, Inc.'s contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by URL Pharma, Inc.. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about URL Pharma, Inc.’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
Phenylketonuria (PKU) (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Phenylketonuria - Drugs in Development, 2021, provides an overview of the Phenylketonuria (Metabolic Disorders) pipeline landscape. Phenylketonuria...
Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 184.108.40.206) - Drugs in Development, 2021 Summary Protein Kinase C Theta Type (nPKC Theta or PRKCQ or EC 220.127.116.11) - Protein kinase C theta (PKC-?) is an enzyme encoded by the PRKCQ gene. It mediates non-redundant functions in T-cell receptor...
Interleukin 1 (IL1) - Drugs in Development, 2021 Summary According to the recently published report ’Interleukin 1 - Drugs in Development, 2021’; Interleukin 1 (IL1) pipeline Target constitutes close to 36 molecules. Out of which approximately 35 molecules are developed by companies and remaining...
The Veterinary Pain management market was valued at USD 1,197 million in 2020, and it is expected to reach USD 1,910 million in 2026, registering a CAGR of nearly 6.30% during the forecast period. The global outbreak of COVID-19 has impacted all industries including veterinary pain medicine. Pet parents are advised to keep a safe distance...
The North America microplate readers market is expected to reach US$ 322.75 million by 2027 from US$ 240.51 million in 2019; it is estimated to grow at a CAGR of 3.8% from 2020 to 2027. The growth of the market is attributed to some key driving factors such as increasing research and development in the pharmaceutical industry and rising development...
120 pages •
By Infiniti Research Limited
• May 2021
Global Microbiomes Market 2021-2025 The analyst has been monitoring the microbiomes market and it is poised to grow by $ 713.01 million during 2021-2025, progressing at a CAGR of over 24% during the forecast period. Our report on microbiomes market provides a holistic analysis, market size and forecast, trends, growth drivers,...
The Alzheimer’s disease diagnostics and therapeutics market was valued at USD 6,632.82 million in 2020, and it is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period, 2021-2026. The study titled, "Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a...
The onychomycosis market estimated to be valued at USD USD 2730.72 million in 2020 and is expected to reach approximately USD 3781.42 million in 2026, registering a CAGR of nearly 5.75% during the forecast period. Prior to the COVID-19 pandemic, clinical examination, dermoscopy, and mycological examination were recommended for all patients...
Hypoglycemia (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Drugs in Development, 2021, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape. Hypoglycemia is a condition...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.